ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
SM Cotton, M Berk, A Watson, S Wood, K Allott, CF Bartholomeusz, CC Bortolasci, K Walder, B O'Donoghue, OM Dean, A Chanen, GP Amminger, PD McGorry, A Burnside, J Uren, A Ratheesh, S Dodd
TRIALS | BMC | Published : 2019
BACKGROUND: First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown that the antioxidant amino acid N-acetylcysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary ai..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council
The project has been funded by the National Health and Medical Research Council (APP1125778). NHMRC has no role in the study design, data collection and analysis, decision to publish, or the preparation of manuscripts.